  Traditionally, optimization of radiation therapy (RT) treatment plans has
been done before the initiation of RT course, using population-wide estimates
for patients' response to therapy. However, recent technological advancements
have enabled monitoring individual patient response during the RT course, in
the form of biomarkers. Although biomarker data remains subject to substantial
uncertainties, information extracted from this data may allow the RT plan to be
adapted in a biologically informative way. We present a mathematical framework
that optimally adapts the treatment-length of an RT plan based on the acquired
mid-treatment biomarker information, while accounting for the inexact nature of
this information. We formulate the adaptive treatment-length optimization
problem as a 2-stage problem, wherein the information about the model
parameters gathered during the first stage influences the decisions in the
second stage. Using Adjustable Robust Optimization (ARO) techniques we derive
explicit optimal decision rules for the stage-2 decisions and solve the
optimization problem. The problem allows for multiple worst-case optimal
solutions. To discriminate between these, we introduce the concept of Pareto
Adjustable Robustly Optimal (PARO) solutions. In numerical experiments using
lung cancer patient data, the ARO method is benchmarked against several other
static and adaptive methods. In case of exact biomarker information, there is
sufficient space to adapt, and numerical results show that taking into account
both robustness and adaptability is not necessary. In case of inexact biomarker
information, accounting for adaptability and inexactness of biomarker
information is particularly beneficial when robustness (w.r.t. organ-at-risk
(OAR) constraint violations) is of high importance. If minor OAR violations are
allowed, a nominal folding horizon approach is a good performing alternative.
